Adverse Factors and the Role of Cisplatin and Vinca Alkaloids for Hearing Impairment in Childhood Cancer Patients and Survivors / 임상소아혈액종양
Clinical Pediatric Hematology-Oncology
;
: 121-129, 2017.
Article
in English
| WPRIM
| ID: wpr-23108
ABSTRACT
BACKGROUND:
Although combined chemotherapy has increased survival rates among children with cancer, such treatments can induce sensorineural hearing loss. Therefore, we aimed to identify risk factors for hearing impairments in patients with childhood cancer.METHODS:
Audiograms were obtained from 115 patients with childhood cancer and survivors (age 20 dB based on the weighted mean value in either ear. Severe hearing impairments were observed in 56% of patients with brain tumors. Although cisplatin or vinca alkaloids were significant risk factors for hearing impairment, the use of both cisplatin and vinca alkaloids exhibited the highest odds ratio for hearing impairment (P < 0.001, < 0.001 for R/LA(max); P=0.099, 0.039 for R/LA(avg)). Multivariate analysis revealed that the use of both cisplatin and vinca alkaloids was an independent risk factor for hearing impairment based on RA(max), LA(max), and LA(avg) (P < 0.001, < 0.001, 0.039, respectively).CONCLUSION:
Our findings indicate that cisplatin and vinca alkaloids exert an additive effect on the risk of hearing impairment in survivors of childhood cancer. Further prospective studies are thus required to determine the most effective chemotherapeutic regimen for reducing ototoxicity.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Audiometry
/
Vinca Alkaloids
/
Brain Neoplasms
/
Odds Ratio
/
Multivariate Analysis
/
Survival Rate
/
Prospective Studies
/
Risk Factors
/
Cisplatin
/
Survivors
Type of study:
Etiology study
/
Observational study
/
Prognostic study
/
Risk factors
Limits:
Child
/
Humans
Language:
English
Journal:
Clinical Pediatric Hematology-Oncology
Year:
2017
Type:
Article
Similar
MEDLINE
...
LILACS
LIS